Pituitary adenomas cause significant endocrine and mass-related morbidity. Little is known about the mechanisms that underlie pituitary tumor pathogenesis. In the present study, we searched for a side population (SP) in pituitary tumors representing cells with high efflux capacity and potentially enriched for tumor stem cells (TSCs). Human pituitary adenomas contain a SP irrespective of hormonal phenotype. This adenoma SP, as well as the purified SP (pSP) that is depleted from endothelial and immune cells, is enriched for cells that express 'tumor stemness' markers and signaling pathways, including epithelial-mesenchymal transition (EMT)-linked factors. Pituitary adenomas were found to contain self-renewing sphere-forming cells, considered to be a property of TSCs. These sphere-initiating cells were recovered in the pSP. Because benign pituitary adenomas do not grow in vitro and have failed to expand in immunodeficient mice, the pituitary tumor cell line AtT20 was further used. We identified a SP in this cell line and found it to be more tumorigenic than the non-SP 'main population'. Of the two EMT regulatory pathways tested, the inhibition of chemokine (C-X-C motif) receptor 4 (CXCR4) signaling reduced EMT-associated cell motility in vitro as well as xenograft tumor growth, whereas the activation of TGFb had no effect. The human adenoma pSP also showed upregulated expression of the pituitary stem cell marker SOX2. Pituitaries from dopamine receptor D2 knockout (Drd2 K/K ) mice that bear prolactinomas contain more pSP, Sox2
Introduction
Pituitary tumors are generally benign adenomas. Radiology and autopsy, being performed for reasons other than pituitary-related medical ones, show a high prevalence of 10-15% in the overall population, although most of these lesions are small and asymptomatic (Daly et al. 2009 , Melmed 2011 . Clinically relevant pituitary adenomas have a lower prevalence of approximately 0.1% (Daly et al. 2009 ), but they still represent the third most frequent intracranial neoplasm, after meningiomas and gliomas. Tumorigenesis in the pituitary can pose serious medical complications. Tumors may hypersecrete one or more of the pituitary hormones, which can lead to severe endocrine disturbances and pernicious effects on the many physiological processes that are governed by the gland. Growth hormone (GH)-producing adenomas (somatotropinomas, GH-A) cause gigantism or acromegaly, adrenocorticotropic hormone (ACTH)-producing tumors (corticotropinomas, ACTH-A) lead to Cushing's disease, and prolactin (PRL)-producing adenomas (prolactinomas, PRL-A) negatively affect gonadal status and reproduction. Conversely, a large number of pituitary tumors do not measurably secrete hormones (i.e., nonfunctioning adenomas (NF-A)), but their growth and expansion may lead to deficient function of the gland (hypopituitarism) and to visual disturbances as a result of the compression of the optic chiasm and nerves. In general, 30-45% of clinically diagnosed adenomas display local expansion as well as invasion of neighboring structures, such as the bony sphenoid sinus and the parasellar venous cavernous sinuses (Galland et al. 2010) . Current therapeutic approaches, which include transsphenoidal resection, pharmacotherapy, and irradiation, remain inadequate in a significant number of patients (Daly et al. 2009 , Galland et al. 2010 . The degree of invasiveness appears to be a critical determinant for the success rate of surgical removal and thus for relapse. At present, the mechanisms that underlie the pathogenic processes of initiation, expansion, invasion, and/or relapse of pituitary tumors are largely unknown. Only a minority of the tumors (approximately 5%) are hereditary and can be traced back to genetic mutations; these exist either as isolated tumors or as a component of a larger endocrine syndrome, like Men-1 (Daly et al. 2009 , Melmed 2011 .
In other types of tumors, so-called cancer stem cells (CSCs) have been identified. CSCs represent a pool of relatively undifferentiated transformed cells that selfrenew and propagate the entire range of tumor cell progeny. Compared with the other cells in the tumor, the CSC subpopulation is considered to be more tumorigenic and more resistant to therapy, thereby surviving treatment and finally regrowing the (heterogeneous) tumor (Vankelecom & Gremeaux 2010 , Clevers 2011 , Vankelecom 2012 , Vankelecom & Chen 2014 . Recently, CSCs have been reported to display characteristics of epithelial-mesenchymal transition (EMT), which may drive these cells in their tumor expansion and invasive activity (Mani et al. 2008 , Morel et al. 2008 , Kong et al. 2010 , Pirozzi et al. 2011 , Yoon et al. 2012 . EMT represents a multi-step cell-conversion process during which epithelial cells gradually acquire mesenchymal features. Cells change morphology, lose polarity and cell-cell contacts (e.g., by loss of E-cadherin), become mobile with enhanced invasive activity, and acquire increased resistance to apoptosis. In general, EMT is known to play a key role in cancer pathogenesis, particularly during the growth, maintenance (including resistance to hostile conditions), and progression of the tumor with local invasion and/or metastasis (De Craene & Berx 2013) . In several types of cancer, it has been shown that EMT markers are enriched in the CSC fraction, that the induction of EMT causes the upregulated expression of 'stemness' genes, and that EMT acts as a key driver in the generation and activity of the CSCs (Mani et al. 2008 , Morel et al. 2008 , Kong et al. 2010 , Pirozzi et al. 2011 , Yoon et al. 2012 .
Although the presence and functional (or clinical) relevance of CSCs has increasingly been documented in a variety of cancers (Clevers 2011 , Eppert et al. 2011 , Schepers et al. 2012 , Boumahdi et al. 2014 , Vanner et al. 2014 , the concept remains the subject of debate and is probably not applicable to all types of cancer. Nonetheless, the model may help us to understand the pathogenesis, therapy resistance, and recurrence of tumors. At present, CSCs have mostly been identified in malignant types of cancer. Whether benign tumors also contain CSCs (in which case they would be better referred to as tumor stem cells (TSCs)) has only limitedly been studied (Vankelecom & Gremeaux 2010 , Lapouge et al. 2011 , Boumahdi et al. 2014 . The search for CSCs is generally performed on the basis of 'stemness'-associated membrane markers or functional traits. High efflux capacity, as mediated by ATP-binding cassette (ABC) multidrug transporters, is considered to be one functional characteristic of CSCs; this property renders the cells more resistant to chemotherapeutic drugs. In the present study, we searched for cells that possess such efflux capacity using the 'side population' (SP) technique (Chen et al. 2005 (Chen et al. , 2009 . Cells that extrude Hoechst dye are observed as a side branch of Hoechst low cells in dual-wavelength fluorescence-activated cell sorting (FACS) analysis. In a variety of cancer types, a SP has been identified and found to be enriched in CSCs or CSC-like cells (Patrawala et al. 2005 , Wu & Alman 2008 , Kato et al. 2010 , Britton et al. 2012 , Moti et al. 2014 . Thus, we searched for SP cells in human pituitary adenomas and in additional models of pituitary tumors (mouse tumors, cell lines, and xenograft tumors). We identified a SP and observed molecular and functional characteristics that are supportive of a TSC-associated phenotype. In addition, we identified the chemokine (C-X-C motif) receptor 4 (Cxcr4) pathway as an interesting target for further investigation in pituitary tumor treatment.
Materials and methods

Pituitary adenomas
Human pituitary adenoma samples were obtained immediately after transsphenoidal resection at the University Hospitals Leuven (Neurosurgery Division). Informed consent was obtained from the patients. Hormonal phenotype was determined by the Department of Imaging and Pathology (University Hospitals Leuven). An overview of the samples with clinical data is provided in Table 1 . Sexes were represented approximately equally with an average age of 53 years (range 19-84 years) at the time of surgery. The majority of the tumors were NF-A (nZ34) and GH-A (nZ21). The other types of resected pituitary tumors were typically microadenomas, which only yielded sufficient study material in a limited number of cases (ACTH-A (nZ3)) or were not surgically removed but were instead treated pharmacologically (resected PRL-A (nZ2)).
Tumor samples were either immediately processed for flow cytometric analysis after resection, or they were cryopreserved as small pieces in Leibovitz-L-15 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS; Lonza, Rockland, ME, USA) and 10% DMSO (Sigma-Aldrich). They were then stored at K196 8C for later examination. The freezing procedure did not change the SP proportion ( Supplementary Fig. S1 , see section on supplementary data given at the end of this article) or the expression characteristics, as was evident from the results of the microarray analyses.
Dissociation of human pituitary adenomas into single cells
Tumor samples were rinsed in DMEM (Life Technologies) supplemented with 0.3% BSA (Serva, Heidelberg, Germany) and incubated with collagenase type IV (1 mg/ml in Medium 199; Life Technologies) for 2-2.5 h at 37 8C. Cell debris was removed by centrifugation through a 3% BSA layer. The resulting cell pellet was resuspended in pituitary-optimized, serum-free chemically defined medium (SFDM, Life Technologies; supplemented with 0.5% BSA; Chen et al. 2005 Chen et al. , 2009 for further analyses.
Immunohistology of human pituitary adenoma sections
Formalin-fixed paraffin-embedded pituitary adenoma blocks were obtained from the Biobank (University Hospitals Leuven). Antigen retrieval was performed on 5 mm sections with EnVision FLEX Target Retrieval Solution (Dako, Glostrup, Denmark). Endogenous peroxidase activity was blocked with EnVision Peroxidase-Blocking Reagent, and sections were incubated with primary antibodies directed against human E-cadherin (readyto-use; Dako), vimentin (VIM; 1:500; Dako), NOTCH2 (1:200; Abcam, Cambridge, UK), and interleukin 6 (IL6; 1:200; Abcam). Subsequently, samples were processed using EnVision Dual Link (Dako). The complex formed was visualized with 3,3 0 -diaminobenzidine (Dako), and sections were counterstained with hematoxylin (Dako).
Isolation and dissociation of mouse pituitaries
C57/Bl6 mice were purchased from Elevage Janvier (BioServices, Uden, The Netherlands), and dopamine receptor D2 knockout (Drd2 K/K ) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were kept or bred in the KU Leuven Animal Facility under The pituitary was isolated from killed mice as previously described (Chen et al. 2005 (Chen et al. , 2009 ). The anterior lobes (anterior pituitary (AP)) of the Drd2 K/K mice that grow prolactinomas (from 6 to 14 months of age; Cristina et al. 2006 ) and those of the respective control mice (Drd2 C/K and Drd2 C/C ) were dispersed into single cells using collagenase type IV as explained in the previous sections for human pituitary adenomas.
Culture and treatment of AtT20
The mouse corticotrope AtT20 cell line was obtained from the American Type Culture Collection (ATCC, CCL-89; Manassas, VA, USA). The cell line was authenticated by hormone expression analysis with quantitative RT-PCR (qRT-PCR; see the subsequent section on qRT-PCR). The cells were cultured in DMEM/F12 (Life Technologies) supplemented with 10% FBS. To investigate the involvement of the transforming growth factor beta (TGFb) or Cxcr4 pathways, AtT20 cells were cultured in serum-free medium for 18-24 h and were then treated with TGFb1 (5 ng/ml; R&D Systems, Minneapolis, MN, USA) or AMD3100 (octahydrochloride, 100 ng/ml; Sigma-Aldrich) respectively. Medium was refreshed every 24 h. To analyze gene expression and SP proportion after treatment (see the subsequent sections on these methods), cells were detached and dissociated using trypsin (0.05%) with EDTA (0.02%; Life Technologies).
Flow cytometry
Dissociated cells (from human adenoma or mouse AP, AtT20 cell line, or xenograft tumors -see subsequent sections) were processed for SP analysis as described in detail previously (Chen et al. 2005 (Chen et al. , 2009 ). In short, cells were incubated with the vital dye Hoechst 33342 (Sigma-Aldrich) at a final concentration of 2.5 mg/ml (for mouse AP and AtT20) or 5 mg/ml (for adenoma and xenograft samples). Subsequently, cells were either immediately analyzed by FACS (Vantage or Aria III; BD Biosciences, Erembodegem, Belgium) or they were first stained with phycoerythrin (PE)-conjugated mouse anti-human CD45, FITC-conjugated mouse anti-human CD31, PE-conjugated mouse anti-mouse CD45, and/or FITC-conjugated rat anti-mouse CD31 antibodies using dilutions recommended by the manufacturer (BD Biosciences). Samples were examined for SP on the basis of dual-wavelength emission using appropriate filters (Vantage: 424/44 and 630/22; Aria III: 450/40 and 630/20) after (near-)u.v. excitation (360 and 375 nm on Vantage and Aria III respectively). The SP phenotype was verified by adding verapamil (100 mM; Sigma-Aldrich), which blocks the Hoechst efflux. The bulk cell population that did not expel Hoechst was designated as the 'main population' (MP). CD31 and CD45 staining was controlled using isotype antibodies (BD Biosciences; data not shown). 2 )!0.52.
To explore the involvement of the Cxcr4 pathway, AtT20 xenograft tumors that developed in SCID mice were treated with AMD3100 by intratumoral injection (5 mg, two times per week) starting from day 21 after the s.c. AtT20 cell implantation.
Tumorsphere-and colony-forming assay Dissociated human pituitary adenoma cells were seeded at a density of 100 000 cells/ml into 35 mm nontreated culture dishes (Iwaki, Scitech, Chiba, Japan) and cultured in SFDM supplemented with B27 (1:50; Life Technologies) and recombinant basic fibroblast growth factor (bFGF, 20 ng/ml; R&D Systems). Fresh medium was added every 3 days. To assess their self-renewal capacity, the spheres were harvested and dissociated into single cells using trypsin (Chen et al. 2009) , and the cells were reseeded under similar conditions.
To evaluate their colony-forming capacity, cells were cultured at low density (1000-4000 cells/60 mm dish) in Ultraculture medium (Life Technologies) to which 5% FBS, 20 ng/ml bFGF, and 50 ng/ml cholera toxin (SigmaAldrich) were added. Medium was changed every 3 days. Cultures were fixed with methanol and stained with 1,9-dimethyl-methylene blue (Sigma-Aldrich), and the number of colonies was determined. Live pictures of the formed spheres and colonies were taken using a Nikon Eclipse TS100 microscope (Nikon Instruments, Melville, NY, USA).
Cell motility assay
Cell motility was evaluated using the 'scratch assay'. After reaching 90% confluence, AtT20 cells were serum-starved for 24 h and then treated with mitomycin C (10 mg/ml; Kyowa, Tokyo, Japan) to inhibit cell proliferation. A straight scratch was created, and cells were further kept in DMEM/F12, together with TGFb1 (5 ng/ml), AMD3100 (100 ng/ml), or vehicle. Medium was changed every 24 h. The migration of cells into the scratch was evaluated by light microscopy, and live pictures were taken with the Nikon Eclipse TS100 microscope at different time points. The open area was calculated using analysisalgorithm-based TScratch Software (CSElab-ETH, Zurich, Switzerland).
Small-animal magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on Drd2 K/K and Drd2 C/K mice using a horizontal 9.4-Tesla nuclear magnetic resonance spectrometer and a 40 mmdiameter birdcage coil as the radio frequency transmitter and receiver. Mice were anesthetized using 1% isoflurane in a mixture of 75% air and 25% oxygen. T1-weighted images were acquired using a two-dimensional multipleslice spin echo sequence, with an echo time of 11 ms, a repetition time of 500 ms, an in-plane resolution of 0.1! 0.1 mm, 24 coronal slices with 0.3 mm slice thickness, and ten signal averages. Image reconstruction was performed using the spectrometer console. Ten minutes before the scanning procedure, mice received an i.p. injection of the contrast agent gadolinium (0.50 mmol/kg body weight).
Immunofluorescence analysis
For the immunofluorescence examination of mouse pituitaries, whole glands were isolated and fixed with paraformaldehyde (4%; Riedel-de Haën, Seelze, Germany). After agarose embedding, pituitaries were coronally sectioned into 45 mm slices using a vibratome (Microm HM 650 V; Prosan, Merelbeke, Belgium). Sections were permeabilized with 0.4% Triton X-100 (Sigma-Aldrich) and incubated overnight with the following primary antibodies: goat anti-human SOX2 (1:750; Immune Systems, Devon, UK) and rabbit anti-mouse PRL (1:10 000; from Dr A F Parlow, NHPP, Harbor-UCLA Medical Center, Torrance, CA, USA). Finally, sections were incubated with AlexaFluor 488-conjugated donkey anti-rabbit and/or AlexaFluor 555-conjugated donkey anti-goat antibodies (1:1000; Life Technologies), and nuclei were labeled with ToPro3 (Life Technologies). Immunofluorescence was examined with a Zeiss LSM 510 confocal laser-scanning microscope (Zeiss, Zaventem, Belgium) accessible through the Cell Imaging Core (CIC; KU Leuven). Z-stacks were collected and analyzed with the Zeiss LSM Image Browser and ImageJ (http://imagej.nih.gov/ij/), and pictures were prepared using the same programs and Microsoft PowerPoint (2007) .
Immunofluorescence staining of paraffin-embedded mouse pituitary sections (5 mm) was performed after antigen retrieval with citrate buffer (pH 6) and permeabilization with Triton X-100 (0.1% in PBS). Following incubation with primary and secondary antibodies (as described earlier), sections were covered with Vectashield (containing 4 0 ,6-diamidino-2-phenylindole (DAPI)) and analyzed with a Leica DM5500 epifluorescence microscope (Leica Microsystems, Diegem, Belgium) accessible through InfraMouse (KU Leuven-VIB). Recorded images were converted to pictures with ImageJ and Microsoft PowerPoint (2007). Cytospin samples of dissociated mouse AP cells were fixed with paraformaldehyde (4%), permeabilized with saponin (0.5%; Sigma-Aldrich), and further immunostained for Sox2 (with goat anti-human SOX2 at 1:250; Immune Systems) as described in the previous sections. In some of the analyses, cells were simultaneously immunostained for the proliferation marker Ki67 (with rabbit anti-Ki67 at 1:50; Thermo Scientific, Fremont, CA, USA). Nuclei were counterstained with DAPI (0.5 mg/ml). To enumerate Sox2-immunopositive cells, pictures were captured using a Leica DM5500 microscope, and cells were counted with ImageJ in five to ten random fields per group in each experiment (about 1500 cells/group in each experiment). The proportions of the Sox2 C cells (of total cells counted) were determined. Because of the increase in total AP cells in the Drd2 K/K adenomatous pituitary, comparison of the proportions is not appropriate. Thus, the absolute numbers of Sox2 C cells were calculated (using their proportion and the total number of AP cells obtained per experimental group of mice) for comparisons between Drd2
, and Drd2 C/C mice. For the immunofluorescence examination of tumorspheres developed from human pituitary adenomas, cells were fixed with paraformaldehyde (4%), permeabilized with Triton X-100 (0.4% in PBS), and incubated with goat anti-human SOX2 (1:250; Immune Systems), rat antimouse nestin (1:500; Abcam), and/or rabbit anti-human GH (for spheres originating from GH-A; 1:2000; Dako). Secondary antibodies included AlexaFluor 555-conjugated donkey anti-goat, AlexaFluor 488-conjugated donkey antirat, and AlexaFluor 488-conjugated donkey anti-rabbit (all at 1:1000; Life Technologies). Pictures were obtained using a Leica DM5500 epifluorescence microscope as described in the previous sections.
AtT20 cell death, apoptosis, and proliferation
The number of dying or dead AtT20 cells after AMD3100 treatment (100 ng/ml) was determined after staining with Trypan blue (0.4%; Sigma-Aldrich). Apoptosis was scored by TUNEL analysis in cytospin samples of AtT20 cells from culture or xenograft tumors using the FragEL Kit (Calbiochem, Darmstadt, Germany). Cell proliferation was quantified by the immunofluorescence staining of cytospin samples for Ki67 as described earlier in the present study. Pictures were taken and cells enumerated (see previous sections).
Whole-genome expression profiling
Total SP and MP cells (NF-A (nZ5) and GH-A (nZ4)) or CD31
K SP (purified SP (pSP)) and pMP cells (NF-A (nZ5)) were sorted by FACS into cold lysis solution of the RNeasy Micro Kit (Qiagen). Total RNA was extracted immediately after cell collection in accordance with the manufacturer's guidelines. RNA samples were stored at K80 8C until further processing for whole-genome expression profiling (in collaboration with the VIB Nucleomics Core, KU Leuven). RNA quality and concentration were determined with Agilent Picochips on an Agilent BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). Two nanograms of high-quality RNA (with RNA integrity number R8.0) was amplified using the NuGen Pico WTA Kit (NuGen Technologies, San Carlos, CA, USA). Cy3 label was incorporated into the cRNA probes, which were then hybridized onto Agilent wholehuman genome 44K oligonucleotide arrays. Slides were scanned and data were processed using Agilent's Feature Extraction Software for background correction, quantile normalization, principal component analysis (PCA), hierarchical clustering, and MA and volcano plots. Microarray data are available from the NCBI's Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/projects/ geo/) through the series accession number GSE62960.
To determine differentially expressed genes (probes), a stringent analysis was initially applied to the normalized data sets. Taking into account that the data are paired (SP versus MP for each sample), analysis was based on the log 2 ratios computed for each pair. Log 2 ratios were compared with the Linear Models for Microarray Data (Limma) package of Bioconductor in R, and a moderated t-statistic (implemented in Limma) was performed to test the significance of the obtained differences. For the first microarray data set (total SP versus MP), the resulting P values were corrected for multiple testing with Benjamini-Hochberg to control the false discovery rate. Differentially expressed genes were withheld when the corrected P value was lower than 0.05. For the second microarray data set (CD31
K MP), Benjamin-Hochberg could not be applied because of the low number of samples. Therefore, a cutoff based on the uncorrected P values (!0.001) was utilized. For both data sets, the cutoff for the P values was combined with a cutoff for the fold change (R2) to finally identify the differentially expressed genes.
Given the rather small number of adenomas analyzed thus far, which causes a very high cutoff for differential expression and hence the discarding of potentially interesting differences, we additionally applied a less stringent analysis by performing paired Student's t-tests on the individual probe sets. Genes were judged to be differentially expressed when P!0.05 and fold change R1.5. We further considered genes that showed a significant expression difference in five to eight out of the nine adenomas analyzed for total SP and MP, and in two to four out of the five adenomas examined for CD31
K fractions. Functional clustering analysis of differentially expressed genes (gene ontology (GO)) was performed using the Database for Annotation, Visualization and Integrated Discovery version 6.7 (DAVID, www.david. abcc.ncifcrf.gov). Gene clusters with an enrichment score of O1.5 (Klog of the median P value for the functional group) were retained. Finally, we narrowed the gene sets by focusing on factors that have been shown to be important in CSC/'tumor stemness', including EMT, NOTCH, WNT/b-CATENIN, and TGFb/BMP.
Gene expression analysis by qRT-PCR
Amplified cDNA of the CD31 K /CD45 K SP and MP fractions from the five microarrayed NF-A samples, as well as that from two additional samples (NF-A (nZ1) and GH-A (nZ1); see Table 1 ), was examined by qRT-PCR to validate the expression of a selection of genes with Fast SYBR Green Master Mix and an ABI 7900HT Fast RT-PCR system according to the manufacturer's instructions (Life Technologies).
Gene expression analysis of AtT20 cells and dispersed xenograft tumors was performed using a similar approach (but without the RNA amplification step). cDNA was subjected to qPCR in a LightCycler 480 with the LightCycler FastStart DNA Master Plus SYBR Green I (Roche).
Forward and reverse primers were designed using PerLPrimer (http://perlprimer.sourceforge.net) or were obtained from a public database (http://medgen.ugent. be/rtprimerdb), and they are described in Supplementary  Table S1 , see section on supplementary data given at the end of this article. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), b2-microglobulin (B2M), and/or hypoxanthine phosphoribosyltransferase 1 (HPRT1) were used to normalize gene expression. Their expression was found to be stable (data not shown). Relative gene expression levels were calculated as change in the threshold cycle (DCt) values ('Ct targetKCt reference') and were compared between the SP and MP as fold change (2 KDCt SP/2 KDCt MP). Statistical analysis was performed using GraphPad Prism version 5.2 (GraphPad Software, La Jolla, CA, USA) by applying Mann-Whitney U tests. P values of !0.05 were considered statistically significant. For authentication of the AtT20 cell line used, hormone gene expression was examined by qRT-PCR. The corticotrope phenotype of the cell line was confirmed by the detection of proopiomelanocortin (POMC; a precursor of ACTH) expression, whereas GH and TSHb gene transcription was not found (see Supplementary  Table S2 , see section on supplementary data given at the end of this article).
Results
Human pituitary tumors contain a SP
Human pituitary adenomas (nZ60; see Table 1) were examined for the presence of a SP. In all of the tumors analyzed, a Hoechst low cell population was detected that was no longer observed when the efflux-blocker verapamil was added together with Hoechst (Fig. 1A) , thereby demonstrating the SP phenotype (mean SPGS.E.M. 1.9G0.3% of the total viable tumor cells; range 0.4-17.2%; Table 1 ). SP proportions were not different between the samples analyzed immediately after surgical resection (nZ26) or those analyzed after cryopreservation (nZ34) ( Table 1 and different hormonal phenotypes examined (Table 1 and Fig. 1B ). The adenoma SP predominantly clusters cells of small to medium size (low 'forward scatter') and low granularity (low 'side scatter') ( Supplementary Fig. S1B ).
Whole-genome expression profiling of the adenoma SP points to EMT and 'tumor stemness' SP cells and the tumor bulk MP cells from somatotropinomas (GH-A (nZ4)) and NF-A (nZ5) (see Table 1 ) were sorted by FACS and subjected to gene expression profiling using whole-genome microarrays. PCA indicated a similar segregation of the SPs from the corresponding MPs for the majority of the samples analyzed ( Supplementary  Fig. S1C ). Hierarchical clustering of differentially expressed genes also largely separated the SPs from the MPs ( Supplementary Fig. S1D ).
The set of genes that was most differentially expressed (P!0.001; 2760 probe sets) was submitted to DAVID for GO analysis, which yielded a total of 1688 corresponding human ENSEMBL IDs. Gene set enrichment exposed in the SP the upregulation of biological functions that are involved in cell proliferation, vascular development, cell migration and motility, and lymphocyte activation (Supplementary Table S3 , see section on supplementary data given at the end of this article).
A focused analysis of a selection of genes using the expression data of the nine adenomas (Table 2 and  Supplementary Table S4 , see section on supplementary data given at the end of this article) revealed upregulated expression (i.e., O1.5-fold in at least two-thirds, or in five, of the nine tumors, P!0.05; see the 'Materials and methods' section) in the SP of the multidrug transporters ABCB1 and ABCG2, which typically underlie the SP phenotype. This finding therefore validates the SP identification and sorting procedure. Remarkably, the transcriptome displayed an expression pattern that supports the occurrence of EMT in the SP compartment. The epithelial markers E-cadherin (CDH1) and claudin-1 (CLDN1) were downregulated in the pituitary adenoma SP, whereas the mesenchymal markers VIM and fibronectin 1 (FN1) were upregulated (Table 2 and Supplementary  Table S4 ). Moreover, recognized markers of EMT, such as SNAI1, ZEB1, and ZEB2 (all of which are transcriptional repressors of the CDH1 gene), were more highly expressed in the SP vs the MP, together with other inductors and regulators of EMT (KLF8, LEF1, TCF4, FOXC1, HOXB9, FOSL2, MMP1/2, and CXCR4). Some of the pathways that were identified as being upregulated are also well known for their regulatory input in EMT (WNT, TGFb, epiregulin, and amphiregulin). In the present analysis, we also observed that factors often associated with 'tumor stemness' or CSCs, including CD44, CXCR4, KIT, KLF4, and NESTIN were up-regulated in the SP. In addition, the signaling pathways of NOTCH, WNT, and TGFb-BMP have also been related to 'tumor stemness'. Overall, no obvious differences were observed between the SP transcriptomes of the NF-A and the GH-A samples.
Notably, the microarray analysis also revealed the upregulated expression of genes associated with an endothelial phenotype (such as PECAM1/CD31, VWF, CDH5, VCAM1, FLK1/KDR, TIE1, and TEK/TIE2) or an immune character (such as CD45/PTPRC) in the adenoma SP (see Table 2 and Supplementary Table S4 ). These expression characteristics are consistent with the enriched biological processes described earlier (viz., vascular development and lymphocyte activation; see Supplementary Table S3 ), and they indicate the presence of endothelial and immune/hematopoietic cells in the SP. Previously, we and others discovered that the SP, either from healthy tissue or tumors, represents a still heterogeneous population that segregates not only cells with (tumor) stem cell properties but also some other cells of endothelial and immune/hematopoietic phenotype (Pfister et al. 2005 , Uezumi et al. 2006 , Chen et al. 2009 ).
Taken together, our microarray expression data indicate that, as compared with the MP, the pituitary adenoma SP is enriched in cells with EMT-and 'tumor stemness'-associated molecular traits, but it is still heterogeneous in cell phenotypes.
EMT-and 'tumor stemness'-related expression characteristics remain present in the adenoma SP depleted from endothelial and immune cells Table 1 ). Also, CD45 C cells were found, but in general they constituted a lower fraction of the adenoma SP (meanGS.E.M. 16.2G3.0% of the SP; range 0.2-66.6%; nZ31; Fig. 1C and D ; Table 1 ). The nonendothelial, non-immune (CD31 K /CD45 K ) SP fraction finally comprised on average one-third of the total SP (meanGS.E.M. 32.3G2.2%; range 7.2-64.1%), 0.5% (G0.1) of all the CD31 K /CD45 K adenoma cells and 0.1% (G0.01) of the total tumor cell population. In general, no correlation was found between the size of the total SP Zinc finger E-box binding homeobox 1 B and the proportion of CD31 C or CD45 C cells (Table 1 and Fig. 1D ), although the two samples with the highest SP proportion analyzed for these antigens (PA 26, and PA 43) contained the largest fractions of CD31 C cells in the SP. To determine the whole-genome expression profiles of the non-endothelial, non-immune cell populations, SP and MP were depleted from CD31 C
/CD45
C cells during flow cytometric sorting (see Fig. 1C for gating; NF-A (nZ5); Table 1 ). Stringent analysis revealed that 101 genes (probe sets), which correspond to 74 human ENSEMBL IDs in DAVID, were differentially expressed between the CD31 K /CD45 K SP (pSP) and the CD31 K /CD45 K MP (pMP). Eighty of these were upregulated in the pSP, and 21 were downregulated ( Supplementary Fig. S2A , B and C, see section on supplementary data given at the end of this article). The relatively small number of samples analyzed thus far caused a high cutoff for differential expression (as is clear in Supplementary Fig. S2A ). Therefore, we performed an additional, less stringent examination (see the 'Materials and methods' section) by analyzing genes that were altered (R1.5-fold, P!0.05) not only in all of the adenomas but also in four out of the five tumors profiled. A total of 2374 genes (probe sets) were found to be differentially expressed in the pSP as compared with the pMP in at least four of the adenoma samples (corresponding to 1576 human ENSEMBL IDs), with 1662 and 712 genes being upregulated and downregulated respectively (Supplementary Table S5 , see section on supplementary data given at the end of this article). The gene sets obtained in both the stringent and less stringent analyses (101 and 2374 genes respectively) were submitted to GO examination using DAVID. Overviews of the most significantly enriched biological processes are provided in Supplementary Tables S6 and S7 , and they include, among others, cell motility and migration, vascular development, cell proliferation, and organ development.
Subsequent analysis of the pSP was focused on a selection of genes as described earlier for the total SP, including genes that are associated with EMT and 'tumor stemness' (Table 3 and Supplementary Table S8 , see section on supplementary data given at the end of this article). On the whole, the expression picture of the total SP appeared to be retrieved in the CD31 K
K SP, viz. The upregulated expression of ABCG2 and of other CSC-associated markers, including CD44, CD34, LIFR, and CXCR4. KIT expression was upregulated in four of the five samples, and NESTIN was upregulated in three of the five (Table 3 ). In particular, the gene expression picture that underlies EMT was also present in the pSP, showing elevated expression of the mesenchymal markers VIM and FN1 and of several transcriptional EMT regulators (including SNAI1, SNAI2, ZEB1, and ZEB2; Table 3 ). Because GO enrichment indicated gene clusters involved in cell motility and migration, and because EMT is known to drive the motile and invasive behavior of cells, additional genes involved in these processes were examined. A considerable number were found to be upregulated or downregulated in the pSP versus the pMP, including EPHB1 and TM4SF1 (Supplementary Table S8 ). Interestingly, epidermal growth factor receptor (EGFR) was also highly (ninefold) upregulated in Expression level of the gene in the total adenoma SP: A, when more than 1.5-fold upregulated in the SP versus the MP in at least two-thirds of the adenoma samples analyzed (six or more out of the nine); B, when more than 1.5-fold upregulated in the SP versus the MP in five out of the nine adenoma samples; C, when more than 1.5-fold downregulated in the SP versus the MP in at least six out of the nine adenoma samples analyzed; and D, when there is less than 1.5-fold difference versus the MP.
the pSP (Supplementary Table S8 ); EGFR has been found to be involved in tumor cell migration in craniopharyngiomas (Hölsken et al. 2011 ). In addition, several components that function in NOTCH, WNT, and TGFb signaling were elevated (Table 3 and Supplementary Table S8 ). These pathways play a role in EMT and 'tumor stemness' but also in pituitary development (Zhu et al. 2007 , Vankelecom 2010 . In general, gene clusters associated with organ development and differentiation processes were found to be enriched in the pSP (see Supplementary Tables S4  and S5 ). Finally, genes that are implicated in angiogenesis were also upregulated in the pSP versus the pMP (Table 3  and Supplementary Tables S6, S7 and S8) . Differential expression as determined from the pSP microarray interrogations was verified by qRT-PCR for a number of the most interesting genes (Fig. 1E) . For these analyses, the five microarrayed NF-A samples were complemented with two additional tumors (one NF-A and one GH-A; see Table 1 ). The results of qRT-PCR essentially confirmed the microarray data, although statistical significance was not always reached in the relatively limited number of samples analyzed thus far. All 17 genes examined showed upregulated expression in the pSP as compared with the pMP (nine with statistical significance, eight with an upward trend; Fig. 1E ). Most remarkable were the elevated expression levels of CD44, IL6, NOTCH2, PDGFRB, SNAI2, VIM, and ZEB2 in the pSP over the pMP (O55-fold). A higher expression level (O55-fold) was also found for CXCR4, FN1, HES1, PDGFC, and TGFBR2, in at least five out of the seven samples. The expression of CDH1 was also checked but was not significantly different in the pSP versus the pMP, although a trend of downregulation was measured in the pSP of four out of the seven adenomas analyzed. The expression of E-cadherin, VIM, IL6, and NOTCH2 was further analyzed by immunohistochemistry in paraffin-embedded sections of pituitary adenomas that were used for the gene expression analysis described earlier in this paper (nZ6; see Table 1 and Supplementary  Fig. S2D ). Tumors with high E-cadherin immunoreactivity contained some zones and cell clusters wherein E-cadherin was downregulated, and VIM was expressed in some regions or in small nests of tumor cells (in addition to the pericapillar cells), which together suggest that some of the tumor cells might have undergone EMT. IL6 immunoreactivity was observed in a couple of clustered cells (two to four per section) in three out of the six adenomas analyzed, and NOTCH2 immunoreactivity occurred in one to two cells per section in four out of the six adenomas (Table 1 and Supplementary Fig. S2D ). IL6 and NOTCH2 immunoreactivity were found in the same adenomas, except for PA 34.
Human pituitary tumors contain sphere-forming cells that segregate to the pSP
TSCs generate spheres ('tumorspheres') when they are brought under appropriate suspension-culture conditions (Vankelecom & Gremeaux 2010 , Clevers 2011 . When pituitary adenoma cells were cultured in the presence of B27 and bFGF, free-floating spheres developed progressively. After 7 days of culture, bright and mostly smooth-edged spheres were obtained that clearly differed from the irregular clumps of aggregated cells that also formed (NF-A and GH-A (nZ13); Fig. 2A and B) . Sphere cells were found to express the stemness markers SOX2 and NESTIN (Chen et al. 2009 ), which thereby supported their TSC character (nZ3; NF-A (nZ1) and GH-A (nZ2); Fig. 2C and Supplementary Fig. S3A and B, see section on supplementary data given at the end of this article). At the end of the culture period (days 7-10), some of the spheres contained cells that expressed the hormone produced by the original tumor, which suggests some degree of spontaneous differentiation and further supports their TSC phenotype ( Supplementary Fig. S3C) . To examine the self-renewal capacity of the sphere-initiating cells (as a further property of TSC), primary spheres were dissociated, and cells were seeded again. Secondary spheres with similar morphology developed, although they were fewer in number (nZ9; Fig. 2D and E), probably because of a considerable loss of cells after the dispersion of the primary spheres. Third-generation spheres were also obtained, but these were still scarcer (Fig. 2F ).
To investigate whether the sphere-forming cells belong to the pituitary tumor's SP, CD31
K /CD45 K SP cells were sorted from adenomas and seeded under sphereforming conditions (nZ3). Spheres developed in the pSP cultures (Fig. 2G ) and were absent from pMP cultures, which contained only irregular clumps of cells (Fig. 2G,  inset) . However, only very few spheres could be obtained (two to four spheres per 20 000 pSP cells originally seeded), which made it impossible to obtain enough viable cells for further passaging after dispersion.
Together, the present findings provide supportive evidence that human pituitary adenomas contain selfrenewing sphere-forming cells that give rise to spheres that express stemness markers, which are considered to be properties of TSCs. The findings further show that the sphere-initiating cells segregate to the pSP.
In addition to the in vitro sphere-forming assay, CSC/TSC activity is typically tested in vivo by (xeno-) transplantation in immunodeficient mice (Vankelecom & Gremeaux 2010 , Clevers 2011 , Schepers et al. 2012 , Boumahdi et al. 2014 . However, we observed that human pituitary adenomas, irrespective of their hormonal phenotype, do not grow (i.e., expand) in immunodeficient SCID mice. Although small tumor pieces survived for 3-4 months after s.c. implantation, no enlargement was detected (data not shown). Xenograft adenoma growth failed not only in SCID mice but also in the more immunodeficient NOD-SCID and NOD/ SCID IL2RgK/K models after the s.c. implantation of the tumor parts as well as the implantation of dissociated cells (data not shown). Similarly, pituitary adenoma fragments engrafted under the kidney capsule survived but did not visibly grow in size (as analyzed after 3-6 months; Supplementary Fig. S4 , see section on supplementary data given at the end of this article). Therefore, to be able to further functionally characterize the pituitary tumor SP and to explore its TSC-associated phenotype, we turned to a well-established pituitary tumor cell line, the mouse corticotrope AtT20, which has previously been shown to grow tumors after s.c. implantation in immunodeficient mice (Taguchi et al. 2006) .
Characterization of AtT20 SP and tumorigenic activity
First, we examined whether the AtT20 cell line contains a SP. A verapamil-blockable Hoechst low cell population was detected that amounted to 1.0G0.3% of the total cells (nZ12; Fig. 3A ). This AtT20 SP showed upregulated expression of the analyzed 'tumor stemness' genes Cd44 and Cxcr4 (Fig. 3B ).
To study in vivo tumorigenic activity, we first verified the tumor-growing capacity of AtT20 cells in SCID mice. The s.c. injection of 5!10 5 cells resulted in a gradually developing tumor ( Supplementary Fig. S5A , see section on supplementary data given at the end of this article), which was palpable after 15-20 days and further expanded in volume until the mouse became moribund, most probably as a result of corticoid overproduction because of increased adrenal stimulation by the AtT20-produced ACTH (Taguchi et al. 2006) . A SP remained present in the AtT20-derived xenograft tumors (as analyzed after 50-55 days), although the proportion was lower than that in the cell line in culture (0.5% versus 1%; nZ3). SP and MP cells were then sorted by FACS from cultured AtT20 cells, and different numbers (10 000, 5000, and 1000 cells) were s.c. injected into SCID mice. Although all of the cell populations induced tumor growth, SP-derived tumors expanded faster (Supplementary Fig. S5B ) and/or became larger ( Fig. 3C and Supplementary Fig. S5B ) as compared with MP-derived tumors. The SP cells developed a tumor with a reconstitution of the SP/MP profile (0.5% SP; nZ2), whereas the MP cells generated tumors with a lower proportion of SP cells (0.2%; nZ2). Together, the present results provide indications that the AtT20 SP has tumorproliferative dominance, and that TSC (and/or TSC-like cells) are enriched, although not exclusively segregated, in the SP.
Effects of EMT regulatory pathways in the AtT20 cell line
As described earlier in the present study, the transcriptomic data of the human pituitary adenomas supported the presence of an EMT process in the (p)SP. Therefore, we tested the effects of two important EMT regulatory pathways (De Craene & Berx 2013) , that is, the TGFb and Cxcr4 pathways, in the AtT20 cell line. Moreover, Cxcr4 has been identified as a marker of CSC(-like cells) in various types of cancer (Hermann et al. 2007 , Vankelecom & Gremeaux 2010 , Clevers 2011 . As mentioned in the previous sections, its expression was upregulated in the human pituitary adenoma pSP and the AtT20 SP (Table 3 ; Figs 1E and 3B). It is worth noting that these studies could not be performed with primary human pituitary adenoma cells, because these cells cannot efficiently be kept in culture and do not grow (well) in vitro (Hofland & Lamberts 2002) .
The treatment of AtT20 cells with TGFb1 for 72 h significantly stimulated the expression of the EMT factors Snai2 and Vim, and there was a clear upward trend for Snai1 and Cxcr4 (Fig. 4A) . However, TGFb1 treatment did not significantly enhance the motility of AtT20 cells, which is an expected functional consequence of EMT (Fig. 4B) . Treatment of AtT20 cells in culture with TGFb1 did not significantly increase the SP proportion (1.2G 0.1% versus 1.0G0.3% in control culture; nZ3; PO0.05). Along the same lines, the pretreatment of AtT20 cells with TGFb1 did not lead to a higher tumor-growing capacity when they were s.c. transplanted into SCID mice, either in terms of onset or in terms of progression (volume expansion) of the tumor (Supplementary Fig. S5C ).
To analyze the involvement of the Cxcr4 pathway, we treated developing AtT20 xenograft tumors in SCID mice with the Cxcr4 antagonist AMD3100. Interestingly, tumors treated with injections of AMD3100 grew at a slower rate and remained smaller than tumors that received injections of vehicle (Fig. 4C) .
We further observed that AMD3100 significantly reduced the migratory activity of AtT20 cells as analyzed in vitro (Fig. 4B) , which thus indicated an effect on EMT. However, AMD3100 treatment did not significantly affect the expression levels of the EMT-associated genes Zeb2, Snai1, Snai2 (although a downward trend was observed), Vim, and Cdh1 or of the CSC-associated marker Cd44, as analyzed in the xenograft tumors after 20 days of treatment (Fig. 4D) . In vitro, 72 h AMD3100 treatment also did not affect the expression levels of these genes, and it had no significant effect (although there was a tendency towards a decrease) on the proportion of the SP (0.5G0.3% vs 0.9G0.2% in controls; nZ3; PO0.05). Notably, there was a small increase in Cxcr4 expression in the AMD3100-treated xenograft tumors (Fig. 4D) ; the upregulation of Cxcr4 after AMD3100 treatment has also been reported in other tumors, supposedly as a result of the adaptation of the tumor to sustained Cxcr4 signal inhibition (Domanska et al. 2012) . Together, EMT genes -at least the ones examined in the present analysis -do not seem to be involved in the AMD3100-induced inhibition of cell motility and of xenograft tumor growth (at least as examined after 20 days of treatment). To search for possible other mechanisms of tumor growth reduction, cell viability and proliferation were evaluated. Treatment of cultured AtT20 cells with AMD3100 resulted in a twofold to threefold increase in dying/dead cells (from 2-4% in controls to 8-11% after AMD3100 treatment; Fig. 4E ). In analogy, AMD3100 augmented the number of AtT20 cells that went into apoptosis (about twofold; Fig. 4F ). However, no difference could be detected in the number of apoptotic cells after the 20-day AMD3100 treatment in vivo (data not shown). The treatment of cultured AtT20 cells with AMD3100 also reduced the proportion of proliferating cells (from about 90 to 60% after 72 h; Fig. 4G) . From these in vitro data, it can be assumed that the tumor-growth-inhibitory effect of AMD3100 at least partially involves a reduction in cell viability and proliferation. From our results so far, there are no indications as of yet that EMT is also implicated.
Pituitary tumorigenesis and pituitary stem cells
In addition to the finding of SOX2 expression in tumorsphere cells, the results of the present microarray analysis also revealed upregulated gene expression of SOX2 in the adenoma pSP (more than 1.5-fold in three of the five human pituitary tumors analyzed; P!0.05). Interestingly, the AtT20 SP also showed higher expression of Sox2 (as compared with the MP; Supplementary Fig. S6A , see section on supplementary data given at the end of this article). A similar finding was observed in an additional pituitary tumor cell line, the rat lactosomatotrope GH3, which also contains a SP (0.5G0.05%; nZ18; Supplementary Fig. S6A and B ). Sox2 is a stemness factor that also marks the recently identified stem cells of the pituitary gland (Chen et al. 2009 ). In general, a link may exist between CSCs/TSCs of tumors in organs and the resident stem cells, as has been recently supported by results from studies of several cancers (Barker et al. 2009 , Llaguno et al. 2009 , Zhu et al. 2009 , Mulholland et al. 2010 , Vankelecom & Gremeaux 2010 , Clevers 2011 , Lapouge et al. 2011 , Schepers et al. 2012 , Boumahdi et al. 2014 , Vankelecom & Chen 2014 , Vanner et al. 2014 .
To explore the pituitary stem cells in connection with the gland's tumors, we turned to the Drd2 K/K mouse model (Cristina et al. 2006) . In the pituitaries of Drd2 K/K female mice, prolactinomas gradually develop starting at 6-8 months of age, which can be detected by MRI and after necropsy ( Supplementary Fig. S7A , see section on supplementary data given at the end of this article). The CD31
K SP (pSP) proportion in the tumor-bearing AP from Drd2 K/K mice (1.7G0.3%; nZ5; Supplementary  Fig. S7B ) was higher than that in heterozygous Drd2 C/K (1.4G0.6%; nZ2) and WT Drd2 C/C control littermates (1.3G0.2%; nZ2). Calculated using absolute cell numbers (see the 'Materials and methods' section), the Drd2 K/K AP contains about tenfold more pSP cells than the control mice (Fig. 5A) . Similarly, the absolute number of colonyforming cells (which is also often used to investigate TSC activity in vitro) was higher in Drd2 K/K than in Drd2
C/K pituitaries (3.9G0.7-fold; nZ3). In addition, colonies that developed from the Drd2 K/K pituitary were generally larger in size and more smoothly shaped than were the colonies that developed from the heterozygous mice ( Supplementary Fig. S7C ).
We next examined the prolactinoma-bearing pituitaries of Drd2 K/K mice for Sox2 C cells. According to countings in dissociated APs (see the 'Materials and methods' section), the absolute number of Sox2 C cells was higher in the Drd2 K/K AP as compared with the WT gland (2.4G0.6-fold; nZ3; Fig. 5B ). At least part of the increase in Sox2
C cells is the result of higher proliferative activity. Whereas proliferating (Ki67 C ) Sox2 C cells were virtually absent in WT Drd2 C/C AP at the ages tested (6-12 months), double Sox2
C /Ki67 C cells were more readily observed in Drd2 K/K AP (Fig. 5C ). Furthermore, as has been shown previously (Chen et al. 2009 , Sox2 immunoreactive signal was not only found in the expected location in the nucleus (nuclear-Sox2 C (nSox2 C ) cells); some cells showed Sox2 C signals in the cytoplasm (cytoplasmic-Sox2 C (cSox2 C ) cells). The Drd2 K/K cSox2 C cells showed a higher increase than the nSox2 C cells as compared with Drd2 C/C WT pituitaries (3.1G0.3-and 2.3G0.7-fold respectively; Fig. 5B and C) . In situ, Sox2
C cells in the Drd2 K/K pituitary were found in the marginal zone bordering the cleft, which is not different from the WT pituitary ( Fig. 5D and Supplementary Fig. S7D ). On top of this location, frequent clusters of Sox2 C cells were observed within the PRL C tumor cell mass in the Drd2 K/K pituitary ( Fig. 5D and Supplementary Fig. S7D ). In the WT gland, Sox2
C cell clusters are also found spread within the endocrine AP parenchyma ( Fig. 5D and Supplementary Fig. S7D ).
Double Sox2
C /PRL C cells were not detected in either of the pituitary phenotypes. Taken together, the number of Sox2 C cells is clearly increased in the Drd2 K/K versus the WT pituitary, but their overall appearance in the putative stem cell niches seems to be not very different.
Discussion
Adenomas represent the most frequent pathology of the pituitary gland. Despite extensive research, not much is known about the mechanisms that underlie pituitary tumor pathogenesis.
In the present study, we demonstrated the existence of a SP in different models of pituitary tumors, including human adenomas, mouse tumors, and cell lines. During the past decade, SPs have been identified in many tumor types and cell lines, and they were often found to be enriched in cells with CSC or CSC-like phenotype or activity (Patrawala et al. 2005 , Wu & Alman 2008 , Kato et al. 2010 , Britton et al. 2012 , Moti et al. 2014 . The majority of these studies looked for CSCs in malignant cancers. The present study is among the first to identify a SP in benign tumors (Wu et al. 2007) . The pituitary adenoma SP still represents a heterogeneous population, similarly to the SPs in other tumors as well as in healthy tissues (Pfister et al. 2005 , Uezumi et al. 2006 . In a previous study, we also detected endothelial-type cells in the SP of the normal (mouse) pituitary; further purification led to the identification of pituitary stem cells (Chen et al. 2009 ). The endothelial-type SP cells of the pituitary tumors may represent a progenitor phenotype that drives angiogenesis during tumor expansion. The presence of endothelial progenitor cells in pituitary adenomas has indeed been suggested based on the detection of CD133, CD34, NESTIN, and VEGFR2 in non-hormonal and non-folliculostellate cells of the tumors (Yunoue et al. 2011) . Notably, the expression picture that was distilled from the total adenoma SP was found to be largely reconfirmed in the purified CD31 K /CD45 K SP (pSP). The results of other studies have also indicated that the expression characteristics of minority CSC fractions can surface in still mixed populations (Eppert et al. 2011) .
Several upregulated genes in the (p)SP were associated with a 'tumor stemness' phenotype, which has also been reported for the SP in other tumors (Patrawala et al. 2005 , Wu & Alman 2008 , Kato et al. 2010 , Britton et al. 2012 , Moti et al. 2014 . In addition, the NOTCH, WNT, and TGFb/BMP pathways represent not only '(tumor) stemness' signaling systems but also regulatory circuits that are well known for their critical role in pituitary embryonic development (Zhu et al. 2007 , Vankelecom 2010 . Moreover, the upregulated expression of NOTCH2 might be remarkable in this sense, because this specific member of the Notch receptor family is particularly highly expressed in the progenitor cells of Rathke's pouch, the embryonic pituitary anlage (Zhu et al. 2007 , Vankelecom 2010 ). This embryonic link may be consistent with the idea that CSCs recapitulate aspects of embryonic development. Results of other studies have also indicated the involvement of NOTCH and WNT signaling in pituitary tumorigenesis, as concluded from the transcriptomic analysis of unfractionated adenomas (Moreno et al. 2005) . Furthermore, the upregulation of HIF2a in the SP may be of importance; in other tumors, such as glioma, HIF2a regulates the tumorigenic capacity of the CSC fraction (Das et al. 2008) . Hypoxia is known to stimulate CXCR4 expression (De Craene & Berx 2013) , which was indeed found to be upregulated in the pituitary tumor (p)SP. In many cancer types, CXCR4 has been advanced as a marker of CSCs, and the pathway is known to play a role in CSC activity (Hermann et al. 2007 , Vankelecom & Gremeaux 2010 , Clevers 2011 . It is also notable that the EGFR pathway substrate 8 (EPS8) was also overexpressed in the pSP in the present study (four of the five adenomas, P!0.05; Supplementary Table S8 ). This oncoprotein has previously been found to be upregulated in multiple pituitary tumor subtypes, where it mediates survival, proliferation, and tumorigenicity (Xu et al. 2009a) . Moreover, the accompanying EGFR was also found to be upregulated and has been shown to be involved in tumor cell migration in some cancers (Hölsken et al. 2011) .
Finally, the present expression data suggest that the PI3/Akt/mTOR/PTEN pathway is also enriched in the adenoma SP (data not shown). This pathway has been proposed to play a role in pituitary tumorigenesis (Dworakowska et al. 2009 ). Moreover, CXCR4 and PI3K/Akt are interconnected; it has been shown that the paracrine/autocrine activation of CXCR4 signaling provokes the Akt-mediated improvement in survival of glioblastoma CSCs (Rubin et al. 2003 , Gatti et al. 2013 . It should be noted that the expression pattern in the pSP only minimally overlaps with the set of genes (CD133, NESTIN, CD90/THY1, OCT4, MSI, JAG2, NOTCH4, and DLL1) that have recently been identified as being upregulated in candidate pituitary TSCs (so-called 'pituitary adenoma stem-like cells' (PASCs)), which were obtained by culture of sphere-like bodies (Xu et al. 2009b) . In the present study, only NOTCH4, DLL1, and NESTIN were found to be overexpressed, with NOTCH4 and DLL1 being upregulated only in the total SP and not in the pSP. Moreover, expression levels of the multidrug transporter genes BCRP1 (ABCG2) and MDR1 (ABCB1) have been reported not to be upregulated in the PASCs (Xu et al. 2009b) . These divergent results could be mainly explained by the use of cultured cells (Xu et al. 2009b) versus cells that were obtained directly from the tumor (the present study; further commented on in Vankelecom (2012) and Vankelecom & Chen (2014) ).
In a recent study (Donangelo et al. 2014) , candidate TSCs were proposed to exist in pituitary tumors that develop in Rb C/K mice. These tumors differ from typical pituitary adenomas (i.e., of the AP), because they arise in the intermediate lobe (IL) of the gland. Stem cell antigen 1 (Sca1)-immunoreactive cells sorted from these IL tumors displayed higher sphere-forming capacity as compared with the Sca1 K cells as well as increased expression of Sox2 and nestin, and tumor-growth advantage after the injection of a large number of cells (10 5 ) into the brain striatum of NOD-SCID IL2RgK/K mice. We previously showed that pituitary 'stemness' is rather accompanied by the absence of Sca1 and that Sca1 expression is mainly found in the endothelial fraction of the SP (Chen et al. 2009 ). These findings were later supported by the detection of Sca1 in progenitor cells of endothelial or mesenchymal origin in mouse pituitary cell lines (Mitsuishi et al. 2013) . Thus, Sca1 expression might represent a difference in the signature of the IL tumor TSCs and the normal pituitary stem cells. Alternatively, Sca1 C cells from the IL tumors may also include endothelial progenitor cells (CD31 C cells were not removed from the Sca1 C fraction), which would facilitate tumor xenograft development by providing angiogenic support and which could be an (additional) explanation for the tumor-growth advantage. Similar to the findings presented here the Sca1 C fraction did not fully retrieve the tumorigenic activity, and Sca1
K cells also formed tumors (although to a lower extent). Intriguingly, in the majority of the xenograft tumors derived from the Sca1 C cell population, Sca1
C cells could no longer be detected, which does not exactly fit with the definition of selfrenewing CSCs. It should also be noted that Sca1 cannot be employed as a (potential) TSC marker in human pituitary adenomas, because this gene (product) does not exist in humans.
In contrast to the highly penetrant Rb C/K IL tumors (Donangelo et al. 2014) , benign human pituitary adenomas (transplanted s.c. or subrenally) did not expand in mice regardless of the grade of immunodeficiency of the mice. Xu et al. (2009b) reported 'growth and reconstitution of the original tumor' from their PASC spheroids (as analyzed for one GH-A) when they were implanted into the forebrain of NOD/SCID mice, but no clearly demarcated tumor or expansion was shown (further reviewed in Vankelecom (2012) and Vankelecom & Chen (2014) ).
Because the standard xenograft assay did not work for the benign human pituitary adenoma, we further turned to in vitro TSC assays and to the well-established pituitary tumor AtT20 cell line. Cultured cell lines are often used as complementary paradigms for studying (candidate) CSCs. Moreover, in cell lines of multiple cancer types, the SP has been found to be enriched for authentic or candidate CSCs (Patrawala et al. 2005 , Wu & Alman 2008 , Kato et al. 2010 , Britton et al. 2012 . First, we discovered that human pituitary adenomas contain self-renewing sphere-forming cells that express the stemness markers SOX2 and NESTIN and that the sphere-initiating cells segregate to the pSP. In addition, the AtT20 cell line also contains a SP that was found to be enriched for cells that are more tumorigenic (i.e., grow faster and larger tumors) than MP cells, that better reconstitute the tumor's original heterogeneity (SP/MP profile) -a further property of CSCs, and that express CSC-associated genes. The segregation of tumorigenic activity in the SP is not absolute, as has also been observed in various other studies on CSCs (Boumahdi et al. 2014 , Vanner et al. 2014 and in the Rb C/K IL tumors mentioned earlier (Donangelo et al. 2014) . Zhu et al. 2009 , Mulholland et al. 2010 , Lapouge et al. 2011 , Schepers et al. 2012 , Boumahdi et al. 2014 , Vanner et al. 2014 . On the other hand, stem cells may not directly be involved; rather, they might become activated when a tumorigenic 'assault' occurs in their tissue (Vankelecom & Gremeaux 2010 , Vankelecom & Chen 2014 . In the present study, we observed that the pSP, the Sox2 C , and the colony-forming cells were increased in number when tumors were present in the pituitary, as indicated by the results of analyses using Drd2 K/K mice, in which prolactinomas develop within their natural microenvironment. These results indicate that the pituitary stem cell compartment is activated during tumorigenesis, at least by a rise in cell number. It should be noted that the populations identified may comprise both the 'normal' pituitary stem cells and the (potentially stem-cell-derived) TSCs or TSC-like cells. At present, it is not possible to distinguish between these two on the basis of the properties analyzed (SP, Sox2 expression, and colony formation). The fact that cell numbers and increments are not identical among the three populations (pSP, Sox2 C , and colonyforming) indicates that they do not fully overlap, as has also been observed previously (Chen et al. 2009 . Moreover, more than one (cancer) stem cell population has also been detected in other tissues and tumors (see, e.g., Zhu et al. 2014) . The finding that these populations expand in number may indicate that the stem cells react during tumorigenesis and that they might play a role in the pathogenic process. Notably, the higher increase in cSox2 C cells in the tumorous pituitary might support a higher differentiation rate toward tumor PRL C cells (Chen et al. 2009 . In addition, Sox2
C cell clusters were often observed within the PRL C tumor cell masses, although they were also scattered over the parenchyma in the normal AP. Whether existing clusters are entrapped during tumor formation or whether they play a more active role in the tumorigenic process, either directly (as origin) or indirectly (as tumorinducing or tumor-tropic), needs to be further clarified (e.g., by lineage tracing). In a recent study, the results of lineage tracing did not reveal a direct link of descent between transgenically Wnt/b-catenin-induced craniopharyngioma in the pituitary and the Sox2 C stem cells. Instead, the findings indicated that the Sox2 C stem cells rather acted as paracrine tumor-activating cells in this model (Andoniadou et al. 2013) . Adamantinomatous craniopharyngioma is a typically pediatric tumor that probably originates from ectopic remnants of Rathke's pouch, and it is thus different from the typical AP tumors. The transcription factor Sox2 itself may also play a role in pituitary tumorigenesis, for example, when it is not properly shut down by the tumor suppressor p27 (at least as demonstrated for intermediate lobe tumors; reviewed by Vankelecom & Chen (2014) ). In addition, Sox2 can act as an oncogene in tissues where it is expressed in the putative stem cells (e.g., lung, esophagus, and skin; Arnold et al. 2011 , Boumahdi et al. 2014 . Moreover, the overexpression of other pituitary stem cell factors (like Prop1) from the early Rathke's pouch state onwards may lead to tumor formation in the gland (reviewed by Vankelecom & Chen (2014) ). Again, Prop1 is not found within the tumors but in non-neoplastic regions surrounding the lesions, which indicates that Prop1 overexpression does not generate tumor-driving stem cells but rather generates trophically supporting cells.
In conclusion, we identified a SP in pituitary tumors that displays TSC-associated molecular and functional characteristics. Identification of this cell population could eventually help us to better understand pituitary tumor pathogenesis, and it may have an effect on the clinical management of the disease. The global molecular profile of the pSP may thereby serve as a valuable source for identifying potentially interesting therapeutic targets for further examination.
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